138 related articles for article (PubMed ID: 26695272)
1. Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.
John C; Herz T; Boos J; Langer K; Hempel G
Talanta; 2016; 146():335-9. PubMed ID: 26695272
[TBL] [Abstract][Full Text] [Related]
2. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
4. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
5. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
6. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
7. Characterizing Non-covalent Protein Complexes Using Asymmetrical Flow Field-Flow Fractionation On-Line Coupled to Native Mass Spectrometry.
Ventouri IK; Chang W; Meier F; Drexel R; Somsen GW; Schoenmakers PJ; de Spiegeleer B; Haselberg R; Astefanei A
Anal Chem; 2023 May; 95(19):7487-7494. PubMed ID: 37146101
[TBL] [Abstract][Full Text] [Related]
8. Asparaginase activities during intensified treatment with pegylated
Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
[TBL] [Abstract][Full Text] [Related]
9. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
10. Novel site-specific PEGylated L-asparaginase.
Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
[TBL] [Abstract][Full Text] [Related]
12. Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials.
Viña-Romero MM; Ramos Díaz R; González García J; Nazco-Casariego G; Díaz-Vera J; Gutiérrez-Nicolás F
J Oncol Pharm Pract; 2021 Jul; 27(5):1102-1105. PubMed ID: 32854574
[TBL] [Abstract][Full Text] [Related]
13. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
Lanvers C; Vieira Pinheiro JP; Hempel G; Wuerthwein G; Boos J
Anal Biochem; 2002 Oct; 309(1):117-26. PubMed ID: 12381370
[TBL] [Abstract][Full Text] [Related]
14. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
15. Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children's plasma.
Zhang Y; Wang Y; Wang R; Shen Y; Xu J; Webster TJ; Fang Y
Int J Nanomedicine; 2018; 13():6337-6344. PubMed ID: 30410325
[TBL] [Abstract][Full Text] [Related]
16. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
Nandy P; Periclou AP; Avramis VI
Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
[TBL] [Abstract][Full Text] [Related]
17. Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach.
Siebel C; Lanvers-Kaminsky C; Alten J; Smisek P; Nath CE; Rizzari C; Boos J; Würthwein G
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):187-198. PubMed ID: 34878584
[TBL] [Abstract][Full Text] [Related]
18. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
19. A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography.
Magri A; Soler MF; Lopes AM; Cilli EM; Barber PS; Pessoa A; Pereira JFB
Anal Bioanal Chem; 2018 Nov; 410(27):6985-6990. PubMed ID: 30155702
[TBL] [Abstract][Full Text] [Related]
20. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.
Müller HJ; Beier R; da Palma JC; Lanvers C; Ahlke E; von Schütz V; Gunkel M; Horn A; Schrappe M; Henze G; Kranz K; Boos J
Cancer Chemother Pharmacol; 2002 Feb; 49(2):149-54. PubMed ID: 11862429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
